Lamotrigine pharmacokinetics in patients receiving felbamate

Barry E. Gidal, Andres Kanner, Melissa Maly, Paul Rutecki, Gary L. Lensmeyer

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Drug interactions can significantly complicate the management of patients receiving multiple medications. It is essential therefore that potential pharmcokinetic interactions be evaluated as new antiepileptic medications are introduced. Lamotrigine (LTG) is a recently marketed medication whose pharmacokinetics are significantly influenced by concomitant drugs. Felbamate (FBM), another relatively new antiepileptic agent has been associated with multiple interactions including both enzyme induction and inhibition. The purpose of the present pilot study was to evaluate potential differences in lamotrigine kinetics in six patients concomitantly receiving FBM compared to five patients receiving lamotrigine as monotherapy. There was no statistically significant differences in either apparent LTG oral clearance (0.026 ± 0.005 vs. 0.024 ± 0.01 l/kg per h, respectively), or in mean elimination half-life (33.7 ± 7.5 vs. 40.2 ± 15.05 h, respectively). Oral clearance values in our patients are also consistent with data reported previously in the literature. Data from this pilot study suggest that a marked effect of FBM upon lamotrigine pharmacokinetics is unlikely.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalEpilepsy Research
Issue number1
StatePublished - Apr 1997
Externally publishedYes


  • Antiepileptic agent
  • Felbamate
  • Lamotrigine pharmokinetics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Lamotrigine pharmacokinetics in patients receiving felbamate'. Together they form a unique fingerprint.

Cite this